What did the FDA approve for upadacitinib in ankylosing spondylitis in 2022?
In 2022, the FDA approved upadacitinib (brand name Rinvoq) for adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This approval used clinical trial evidence submitted to support both safety and effectiveness in that patient population.
What dose and key restrictions applied to the FDA-approved use?
The FDA labeling for Rinvoq includes dosing guidance and safety monitoring requirements typical for JAK inhibitors, including boxed warnings for serious heart-related events, cancer, blood clots, and serious infections, as well as specific precautions around infections and lab monitoring. Those labeling elements govern how clinicians use upadacitinib once prescribed for AS.
Which trial evidence supported the 2022 ankylosing spondylitis approval?
The approval relied on randomized clinical trial data evaluating upadacitinib in ankylosing spondylitis, including clinical response outcomes and safety/tolerability results compared with placebo and/or active control as described in the FDA review package and labeling materials.
Who is eligible to use it under the 2022 indication?
Under the approved AS indication in 2022, eligible patients are adults with active ankylosing spondylitis who either did not respond adequately to TNF blockers or could not tolerate them. That requirement is central to how the FDA-defined indication limits use.
How does this approval fit with other upadacitinib FDA indications?
Upadacitinib had already received FDA approvals for other inflammatory and immune-mediated conditions before 2022. The AS approval added another indication within the same mechanism class (JAK inhibition), using condition-specific efficacy and safety data rather than treating it as interchangeable across diseases.
Where can you find the FDA approval and the exact label language?
For the most precise indication wording (including the “TNF blocker” requirement, population language, and safety-related labeling sections), check the FDA-approved prescribing information for Rinvoq and the FDA review/labeling documents for the AS approval. If you want a patent/exclusivity lens as well, DrugPatentWatch.com tracks drug patent information and can be useful for understanding the intellectual-property landscape around Rinvoq. [1]
Sources:
1. DrugPatentWatch.com – Rinvoq (upadacitinib) patent/exclusivity info